Cintas Corporation
—- Market cap
- $80.75B
- Debt
- —
- Cash
- −$289.02M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $80.75B · View financials
Snapshot Sep 11, 2026, 11:02 AM ET
Decision snapshot: CTAS stock price near parity vs VRTX $201.78 current versus $164.61 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VRTX's multiple
Implied fair value · at CTAS's multiple
Snapshot Sep 11, 2026, 11:02 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Cintas Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
VERTEX PHARMACEUTICALS INC / MA · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
UNIFIRST CORP
CTAS vs UNF
ABM INDUSTRIES INC /DE/
CTAS vs ABM
Aramark
CTAS vs ARMK
W.W. GRAINGER, INC.
CTAS vs GWW
INTUIT INC.
CTAS vs INTU
IRON MOUNTAIN INC
CTAS vs IRM
AMGEN INC
CTAS vs AMGN
Gilead Sciences, Inc.
CTAS vs GILD
BIOGEN INC.
CTAS vs BIIB
Moderna, Inc.
CTAS vs MRNA
Illumina, Inc.
CTAS vs ILMN
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.